TODAY.AZ / World news

Japan's Shionogi says COVID pill reaches endpoint in Phase III trial

28 September 2022 [22:15] - TODAY.AZ

By Trend

Japan's Shionogi & Co Ltd said on Wednesday its oral treatment for COVID-19 demonstrated a significant reduction in symptoms compared to a placebo in a Phase III trial in Asia, Trend reports citing Reuters.

The drug, a protease inhibitor known as ensitrelvir, met its primary endpoint in a trial conducted among predominantly vaccinated patients with mild to moderate cases of COVID-19, the company said in a statement.

Regulatory authorities in Japan previously denied emergency approval for use of the pill, saying they wanted to see more data on its effectiveness. read more

Shionogi has global aspirations for the drug, also known as S-217622 and by the brand name Xocova, which would compete with COVID-19 pills from U.S. Pfizer Inc and Merck & Co Inc (MRK.N) that have already been approved in Japan and elsewhere.

The company has signed an agreement to sell about a million doses to the government, pending the drug's approval.

URL: http://www.today.az/news/regions/226108.html

Print version

Views: 449

Connect with us. Get latest news and updates.

Recommend news to friend

  • Your name:
  • Your e-mail:
  • Friend's name:
  • Friend's e-mail: